JP2005526723A - バニロイド受容体モジュレーター - Google Patents

バニロイド受容体モジュレーター Download PDF

Info

Publication number
JP2005526723A
JP2005526723A JP2003567880A JP2003567880A JP2005526723A JP 2005526723 A JP2005526723 A JP 2005526723A JP 2003567880 A JP2003567880 A JP 2003567880A JP 2003567880 A JP2003567880 A JP 2003567880A JP 2005526723 A JP2005526723 A JP 2005526723A
Authority
JP
Japan
Prior art keywords
methyl
mmol
carboxamide
alkyl
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003567880A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005526723A5 (enExample
Inventor
ハーシャド・カンティラル・ラミ
マービン・トンプソン
グレゴー・ジェイムズ・マクドナルド
スーザン・マリー・ウエスタウェイ
ダーレン・ジェイソン・ミッチェル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0203680A external-priority patent/GB0203680D0/en
Priority claimed from GB0203677A external-priority patent/GB0203677D0/en
Priority claimed from GB0203673A external-priority patent/GB0203673D0/en
Priority claimed from GB0209003A external-priority patent/GB0209003D0/en
Priority claimed from GB0209032A external-priority patent/GB0209032D0/en
Priority claimed from GB0209035A external-priority patent/GB0209035D0/en
Priority claimed from GB0221318A external-priority patent/GB0221318D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of JP2005526723A publication Critical patent/JP2005526723A/ja
Publication of JP2005526723A5 publication Critical patent/JP2005526723A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Quinoline Compounds (AREA)
JP2003567880A 2002-02-15 2003-02-13 バニロイド受容体モジュレーター Pending JP2005526723A (ja)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
GB0203680A GB0203680D0 (en) 2002-02-15 2002-02-15 Novel compounds
GB0203677A GB0203677D0 (en) 2002-02-15 2002-02-15 Novel compounds
GB0203673A GB0203673D0 (en) 2002-02-15 2002-02-15 Novel compounds
GB0209003A GB0209003D0 (en) 2002-04-19 2002-04-19 Novel compounds
GB0209032A GB0209032D0 (en) 2002-04-19 2002-04-19 Novel compounds
GB0209035A GB0209035D0 (en) 2002-04-19 2002-04-19 Novel compounds
GB0221318A GB0221318D0 (en) 2002-09-13 2002-09-13 Novel compounds
PCT/GB2003/000608 WO2003068749A1 (en) 2002-02-15 2003-02-13 Vanilloid receptor modulators

Publications (2)

Publication Number Publication Date
JP2005526723A true JP2005526723A (ja) 2005-09-08
JP2005526723A5 JP2005526723A5 (enExample) 2006-03-09

Family

ID=27739514

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003567880A Pending JP2005526723A (ja) 2002-02-15 2003-02-13 バニロイド受容体モジュレーター

Country Status (10)

Country Link
US (1) US7538121B2 (enExample)
EP (2) EP2033953A1 (enExample)
JP (1) JP2005526723A (enExample)
AR (1) AR038420A1 (enExample)
AT (1) ATE416168T1 (enExample)
AU (1) AU2003245773A1 (enExample)
DE (1) DE60325025D1 (enExample)
ES (1) ES2316777T3 (enExample)
TW (1) TW200403223A (enExample)
WO (1) WO2003068749A1 (enExample)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2004103954A1 (ja) * 2003-05-20 2006-07-20 味の素株式会社 アミド誘導体
JP2007502258A (ja) * 2003-08-14 2007-02-08 グラクソ　グループ　リミテッド バニロイド受容体モジュレーターとして用いるためのピペリジン／シクロヘキサンカルボキサミド誘導体
JP2009531373A (ja) * 2006-03-27 2009-09-03 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ キナーゼ阻害剤としてのピリジル及びピリミジニル置換されたピロール、チオフェン及びフラン誘導体
JP2009541206A (ja) * 2006-03-16 2009-11-26 レノビス， インコーポレイテッド Ｐ２ｘ７調節因子としてのビシクロへテロアリール化合物およびその使用
JP2010512305A (ja) * 2006-10-23 2010-04-22 ファイザー株式会社 置換フェニルメチルビシクロカルボキシアミド化合物
JPWO2008091021A1 (ja) * 2007-01-24 2010-05-20 持田製薬株式会社 ヘテロシクリデン−ｎ−（アリール）アセトアミド誘導体
JP2010516662A (ja) * 2007-01-19 2010-05-20 サノフイ−アベンテイス Ｎ−（ヘテロアリール）−１−ヘテロアリール−１ｈ−インドール−２−カルボキサミドの誘導体、これらの調製およびこれらの治療用途
JP2011510052A (ja) * 2008-01-23 2011-03-31 サノフイ−アベンテイス シラニル基で置換されたインドール−２−カルボキサミドおよびアザインドール−２−カルボキサミドの誘導体、この調製、およびこの治療的使用
JP2015501826A (ja) * 2011-12-16 2015-01-19 ロレアル ７−アミノ−１，２，３，４−テトラヒドロキノリン構造を有するカプラー、それを含む染色組成物、方法及び使用
WO2016039448A1 (ja) * 2014-09-12 2016-03-17 田辺三菱製薬株式会社 芳香族カルボン酸アミド化合物

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003212882A1 (en) 2002-02-01 2003-09-02 Euro-Celtique S.A. 2 - piperazine - pyridines useful for treating pain
US6974818B2 (en) 2002-03-01 2005-12-13 Euro-Celtique S.A. 1,2,5-thiadiazol-3-YL-piperazine therapeutic agents useful for treating pain
AU2003241453A1 (en) 2002-05-17 2003-12-02 Janssen Pharmaceutica N.V. Aminotetralin-derived urea modulators of vanilloid vr1 receptor
DE60318875T2 (de) 2002-06-28 2009-01-15 Euro-Celtique S.A. Therapeutische piperazin-derivate für die behandlung von schmerzen
US7262194B2 (en) 2002-07-26 2007-08-28 Euro-Celtique S.A. Therapeutic agents useful for treating pain
GB0221157D0 (en) * 2002-09-12 2002-10-23 Glaxo Group Ltd Novel treatment
US7157462B2 (en) 2002-09-24 2007-01-02 Euro-Celtique S.A. Therapeutic agents useful for treating pain
GB0226724D0 (en) * 2002-11-15 2002-12-24 Merck Sharp & Dohme Therapeutic agents
CA2508618C (en) * 2002-12-06 2012-02-21 Bayer Healthcare Ag Tetrahydro-naphthalene derivatives
AU2003288200A1 (en) * 2002-12-09 2004-06-30 Bayer Healthcare Ag Tetrahydro-naphthalene derivatives as vanilloid receptor antagonists
US20060100245A1 (en) * 2002-12-19 2006-05-11 Neurogen Corporation Substituted biphenyl-4-carboxylic acid arylamide analogues
SE0301446D0 (sv) 2003-05-16 2003-05-16 Astrazeneca Ab New Compounds
AR044688A1 (es) 2003-06-12 2005-09-21 Euro Celtique Sa Agentes terapeuticos utiles para el tratamiento del dolor
AU2004247559B2 (en) * 2003-06-12 2009-08-27 Astellas Pharma Inc. Benzamide derivative or salt thereof
NZ545447A (en) * 2003-07-23 2010-03-26 Synta Pharmaceuticals Corp Compounds for inflammation and immune-related uses
ES2327684T3 (es) 2003-07-24 2009-11-02 Euro-Celtique S.A. Compuestos heteroaril-tetrahidropiridilo utiles para el tratamiento o la prevencion del dolor.
GB0319151D0 (en) * 2003-08-14 2003-09-17 Glaxo Group Ltd Novel compounds
MXPA06003123A (es) * 2003-09-22 2006-05-31 Euro Celtique Sa Agentes terapeuticos utiles para el tratamiento del dolor.
SI1664041T1 (sl) 2003-09-22 2008-12-31 Euro Celtique Sa Fenil-karboksamidne spojine, uporabne za tretiranje bolečine
JP4833069B2 (ja) * 2003-10-01 2011-12-07 ゼンション・リミテッド テトラヒドロ−ナフタレンおよび尿素誘導体
WO2005034870A2 (en) * 2003-10-07 2005-04-21 Renovis, Inc. Amide compounds and ion channel ligands and uses thereof
WO2005046683A1 (en) 2003-10-07 2005-05-26 Renovis, Inc. Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
GB2413129A (en) * 2003-10-07 2005-10-19 Renovis Inc Aromatic amide compounds as ion channel ligands and uses thereof
JP2007518816A (ja) * 2004-01-23 2007-07-12 アムジエン・インコーポレーテツド バニロイド受容体リガンド及び炎症性及び神経因性疼痛の治療におけるこれらの使用
US7544803B2 (en) 2004-01-23 2009-06-09 Amgen Inc. Vanilloid receptor ligands and their use in treatments
WO2006004793A2 (en) * 2004-06-28 2006-01-12 Janssen Pharmaceutica Nv Hetero isonipecotic modulators of vanilloid vr1 receptor
WO2006006740A1 (ja) * 2004-07-14 2006-01-19 Japan Tobacco Inc. ３−アミノベンズアミド化合物及びバニロイド受容体１型(ｖｒ１)活性阻害剤
KR101042490B1 (ko) 2004-07-15 2011-06-16 니뽄 다바코 산교 가부시키가이샤 축합 벤즈아미드 화합물 및 바닐로이드 수용체 1형(ｖｒ1)활성 저해제
WO2006058338A2 (en) * 2004-11-29 2006-06-01 Janssen Pharmaceutica N.V. 4 - piperidinecarboxamide derivatives as modulators of vanilloid vr1 receptor
FR2880625B1 (fr) 2005-01-07 2007-03-09 Sanofi Aventis Sa Derives de n-(heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
KR20060087386A (ko) 2005-01-28 2006-08-02 주식회사 대웅제약 신규 벤조이미다졸 유도체 및 이를 함유하는 약제학적조성물
US7576099B2 (en) 2005-02-28 2009-08-18 Renovis, Inc. Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
FR2888847B1 (fr) * 2005-07-22 2007-08-31 Sanofi Aventis Sa Derives de n-(heteriaryl)-1-heteorarylalkyl-1h-indole-2- carboxamides, leur preparation et application en therapeutique
FR2888848B1 (fr) * 2005-07-22 2007-09-28 Sanofi Aventis Sa Derives de n-(arylalkyl)-1h-pyrrrolopyridine-2-carboxamides, leur preparation et leur application en therapeutique
JP4754566B2 (ja) * 2005-07-22 2011-08-24 持田製薬株式会社 新規なヘテロシクリデンアセトアミド誘導体
US7429605B2 (en) 2005-08-04 2008-09-30 Hoffmann-La Roche Inc. Phenylpyridine derivatives
EP1917245A1 (de) 2005-08-21 2008-05-07 Abbott GmbH & Co. KG Heterocyclische verbindungen und ihre verwendung als bindungspartner für 5-ht5-rezeptoren
DE102005059479A1 (de) * 2005-12-13 2007-06-14 Merck Patent Gmbh Hydroxychinolinderivate
UY30048A1 (es) 2005-12-23 2007-07-31 Astrazeneca Ab Derivados sustituidos de la n,2-(1h-benzimidazol-1-il) acetamida, composiciones farmacéuticas conteniéndolos, procesos de preparación y aplicaciones
JP4086895B2 (ja) 2005-12-28 2008-05-14 日本たばこ産業株式会社 ３，４−ジヒドロベンゾオキサジン化合物及びバニロイド受容体１型（ｖｒ１）活性阻害剤
US7906508B2 (en) * 2005-12-28 2011-03-15 Japan Tobacco Inc. 3,4-dihydrobenzoxazine compounds and inhibitors of vanilloid receptor subtype 1 (VRI) activity
CA2656875C (en) * 2006-07-11 2011-09-06 Pfizer Inc. Substituted n-bicyclicalkyl bicyclic carboxyamide compounds
TWI433839B (zh) 2006-08-11 2014-04-11 Neomed Inst 新穎的苯并咪唑衍生物290
EP2069302B1 (en) 2006-09-15 2010-08-25 Pfizer Inc. Substituted pyridylmethyl bicyclocarboxyamide compounds
WO2008057300A2 (en) * 2006-10-27 2008-05-15 Redpoint Bio Corporation Trpvi antagonists and uses thereof
ATE509925T1 (de) * 2006-11-17 2011-06-15 Pfizer Substituierte bicyclocarbonsäureamidverbindungen
FR2910473B1 (fr) 2006-12-26 2009-02-13 Sanofi Aventis Sa Derives de n-(amino-heteroaryl)-1h-pyrrolopyridine-2- carboxamides, leur preparation et leur application en therapeutique.
US8455513B2 (en) * 2007-01-10 2013-06-04 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
FR2911605B1 (fr) 2007-01-19 2009-04-17 Sanofi Aventis Sa Derives de pyrrolopyridine-2-carbowamides, leur preparation et leur application en therapeutique
US20080186971A1 (en) * 2007-02-02 2008-08-07 Tarari, Inc. Systems and methods for processing access control lists (acls) in network switches using regular expression matching logic
EP2142529B1 (en) * 2007-04-27 2013-12-25 Purdue Pharma LP Trpv1 antagonists and uses thereof
CA2685121A1 (en) 2007-04-27 2008-11-06 Purdue Pharma L.P. Therapeutic agents useful for treating pain
EP2234487A4 (en) * 2007-12-19 2011-09-07 Scripps Research Inst ANILIDES AND ANALOGUES AS INHIBITORS OF RHO KINASE
EP2234618A4 (en) * 2007-12-21 2011-04-27 Scripps Research Inst BENZOPYRANE AND ANALOGUE AS RHO KINASE INHIBITORS
JP2011507850A (ja) * 2007-12-21 2011-03-10 ザ スクリプス リサーチ インスティチュート Ｒｈｏキナーゼインヒビターとしてのアニリドおよびアナログ
FR2926554B1 (fr) 2008-01-22 2010-03-12 Sanofi Aventis Derives de carboxamides azabicycliques, leur preparation et leur application en therapeutique
CN101983197B (zh) 2008-04-18 2015-04-22 大熊制药株式会社 新型苯并噁嗪苯并咪唑衍生物、含有该衍生物的药物组合物及其用途
US8450344B2 (en) 2008-07-25 2013-05-28 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
WO2010126626A2 (en) 2009-05-01 2010-11-04 Aerie Pharmaceuticals, Inc. Dual mechanism inhibitors for the treatment of disease
JP5732453B2 (ja) 2009-06-25 2015-06-10 アルカーメス ファーマ アイルランド リミテッド Ｎｈ酸性化合物のプロドラッグ
PT2445502T (pt) 2009-06-25 2017-09-22 Alkermes Pharma Ireland Ltd Compostos heterocíclicos para o tratamento de distúrbios neurológicos e psicológicos
EP2563759B1 (en) * 2010-04-27 2022-04-06 Calcimedica, Inc. Compounds that modulate intracellular calcium
NZ604423A (en) 2010-06-24 2015-01-30 Alkermes Pharma Ireland Ltd Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
KR101293384B1 (ko) 2010-10-13 2013-08-05 주식회사 대웅제약 신규 피리딜 벤조옥사진 유도체, 이를 포함하는 약학 조성물 및 이의 용도
ES2972387T3 (es) 2011-03-18 2024-06-12 Alkermes Pharma Ireland Ltd Composiciones farmacéuticas que comprenden ésteres de sorbitán
RS55701B1 (sr) 2011-06-22 2017-07-31 Purdue Pharma Lp Trpv1 antagonisti koji uključuju dihidroksi supstituent i njihove upotrebe
WO2013088255A1 (en) 2011-12-15 2013-06-20 Alkermes Pharma Ireland Limited Prodrugs of secondary amine compounds
FR2984318B1 (fr) 2011-12-16 2014-06-27 Oreal Coupleur de structure 7 amino-1,2,3,4-tetrahydroquinoleines cationiques, composition tinctoriale en comprenant, procedes et utilisations
US9999670B2 (en) 2012-03-19 2018-06-19 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising benzyl alcohol
WO2013142202A1 (en) 2012-03-19 2013-09-26 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising glycerol esters
CA2867121C (en) 2012-03-19 2021-05-25 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising fatty acid esters
JP6654042B2 (ja) 2012-09-19 2020-02-26 アルカームス ファーマ アイルランド リミテッド 貯蔵安定性が改善された医薬組成物
US8987461B2 (en) 2012-12-06 2015-03-24 Quanticel Pharmaceuticals, Inc. Histone demethylase inhibitors
ES2776199T3 (es) 2013-03-15 2020-07-29 Aerie Pharmaceuticals Inc Conjugados de compuestos de isoquinolina y prostaglandinas
AU2015231278B2 (en) 2014-03-20 2020-01-23 Alkermes Pharma Ireland Limited Aripiprazole formulations having increased injection speeds
CN107108581B (zh) * 2014-08-21 2020-06-23 百时美施贵宝公司 作为强效rock抑制剂的回接苯甲酰胺衍生物
WO2018045091A1 (en) 2016-08-31 2018-03-08 Aerie Pharmaceuticals, Inc. Ophthalmic compositions
WO2018085348A1 (en) * 2016-11-03 2018-05-11 Actavalon, Inc. Substituted quinolines and methods for treating cancer
US9840468B1 (en) 2016-12-30 2017-12-12 Aerie Pharmaceuticals, Inc. Methods for the preparation of 6-aminoisoquinoline
IT201700028127A1 (it) 2017-03-14 2018-09-14 Fondazione St Italiano Tecnologia Composti e composizioni per il trattamento della fibrosi cistica
CA3057872A1 (en) 2017-03-31 2018-10-04 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds
FR3072286B1 (fr) 2017-10-13 2022-08-12 Oreal 7-amino-1,2,3,4-tetrahydroquinoleines particuliers, procede et composition
AU2019230014B2 (en) 2018-03-05 2024-11-28 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
AU2019337703B2 (en) 2018-09-14 2023-02-02 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds
CN112574106B (zh) * 2020-11-11 2022-04-12 苏州康润医药有限公司 7-氨基-5-溴喹啉的合成方法
DE102022104759A1 (de) 2022-02-28 2023-08-31 SCi Kontor GmbH Co-Kristall-Screening Verfahren, insbesondere zur Herstellung von Co-Kristallen

Citations (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3200123A (en) * 1962-01-26 1965-08-10 Richardson Merreil Inc Imidazoquinolines
JPS4824396B1 (enExample) * 1970-09-09 1973-07-20
WO1996040640A1 (en) * 1995-06-07 1996-12-19 Pfizer Inc. BIPHENYL-2-CARBOXYLIC ACID-TETRAHYDRO-ISOQUINOLIN-6-YL AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND/OR APOLIPOPROTEIN B (Apo B) SECRETION
JPH10291988A (ja) * 1997-04-15 1998-11-04 Fujisawa Pharmaceut Co Ltd 複素環式化合物
JPH11335355A (ja) * 1998-03-26 1999-12-07 Japan Tobacco Inc アミド誘導体及びノシセプチンアンタゴニスト
WO2000069849A1 (en) * 1999-05-12 2000-11-23 Ortho-Mcneil Pharmaceutical, Inc. Pyrazole carboxamides useful for the treatment of obesity and other disorders
WO2000073283A1 (en) * 1999-06-02 2000-12-07 Nps Pharmaceuticals, Inc. Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases
JP2001139555A (ja) * 1999-11-10 2001-05-22 Pfizer Prod Inc ７−［（４’−トリフルオロメチル−ビフェニル−２−カルボニル）アミノ］−キノリン−３−カルボン酸アミド、及びアポリポタンパク質ｂの分泌阻害方法
JP2001508402A (ja) * 1997-06-13 2001-06-26 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 置換ベンズアミド誘導体およびそれらの抗痙攣薬としての使用
JP2001515504A (ja) * 1997-03-18 2001-09-18 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 置換イソキノリン誘導体およびその抗痙攣薬としての使用
JP2001521026A (ja) * 1997-10-24 2001-11-06 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 置換イソキノリン誘導体および抗痙攣薬としての使用
JP2001524116A (ja) * 1997-04-18 2001-11-27 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー ５ｈｔ１ａ、５ｈｔ１ｂおよび５ｈｔ１ｄ受容体アンタゴニスト活性を合わせ持つインドール誘導体
WO2002008221A2 (en) * 2000-07-20 2002-01-31 Neurogen Corporation Capsaicin receptor ligands
JP2002241274A (ja) * 2000-04-28 2002-08-28 Takeda Chem Ind Ltd メラニン凝集ホルモン拮抗剤
JP2004059567A (ja) * 2001-10-25 2004-02-26 Takeda Chem Ind Ltd キノリン化合物
JP2004535456A (ja) * 2001-07-02 2004-11-25 アクゾ・ノベル・エヌ・ベー テトラヒドロキノリン誘導体
JP2005518365A (ja) * 2001-11-27 2005-06-23 メルク　エンド　カムパニー　インコーポレーテッド ４−アミノキノリン化合物
JP2005519876A (ja) * 2001-11-27 2005-07-07 メルク　エンド　カムパニー　インコーポレーテッド ２−アミノキノリン化合物
JP2006505494A (ja) * 2002-02-20 2006-02-16 アボット・ラボラトリーズ バニロイド受容体サブタイプ１（ｖｒ１）受容体を阻害する縮合アザ二環式化合物

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3424761A (en) 1966-03-07 1969-01-28 Robins Co Inc A H 3-ureidopyrrolidines
US3424760A (en) 1966-03-07 1969-01-28 Robins Co Inc A H 3-ureidopyrrolidines
DE2502588A1 (de) 1975-01-23 1976-07-29 Troponwerke Dinklage & Co Basisch substituierte derivate des 7-amino-2-chinolons, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
US4456604A (en) 1981-05-26 1984-06-26 Merck & Co., Inc. 1-(3-Halo-2-pyridinyl) piperazine
DE3475305D1 (en) 1983-07-05 1988-12-29 Pfizer Carboxylic acid derivatives useful for inhibiting the degradation of cartilage
US4803162A (en) * 1984-05-15 1989-02-07 Fluorodiagnostic Limited Partners Composition, article and process for detecting a microorganism
WO1988003137A1 (en) 1986-10-28 1988-05-05 Smith Kline & French Laboratories Limited Tetrahydroisoquinolin-2-yl derivatives of carboxylic acids as thromboxane a2 antagonists
DE3701277A1 (de) * 1987-01-17 1988-07-28 Boehringer Mannheim Gmbh Neue tricyclische benzimidazole, verfahren zu ihrer herstellung und verwendung als arzneimittel
DE68918991T2 (de) 1988-06-17 1995-04-27 Procter & Gamble Anwendung von Vanillin-Derivaten zur Herstellung eines Arzneimittels zur Behandlung von Herpes simplex-Infektion.
HU206082B (en) 1988-12-23 1992-08-28 Sandoz Ag Process for producing capsaicin derivatives and pharmaceutical compositions comprising such compounds
CA2017383A1 (en) 1989-06-08 1990-12-08 Raymond R. Martodam Use of vanilloids for the treatment of respiratory diseases or disorders
AU9079491A (en) 1990-11-27 1992-06-25 Procter & Gamble Company, The Combinations of vanilloid compounds and phosphonate antiviral compounds for treatment of herpes infections
US5342851A (en) 1992-10-07 1994-08-30 Mcneil-Ppc, Inc. Substituted thiazole derivatives useful as platelet aggregation inhibitors
DE4234295A1 (de) 1992-10-12 1994-04-14 Thomae Gmbh Dr K Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
WO1994014801A1 (en) 1992-12-29 1994-07-07 Smithkline Beecham Plc Heterocyclic urea derivatives as 5ht2c and 5ht2b antagonists
ATE360617T1 (de) 1994-06-15 2007-05-15 Otsuka Pharma Co Ltd Benzoheterocyclische verbindungen verwendbar als vasopressin- oder oxytocin-modulatoren
GB9416972D0 (en) 1994-08-23 1994-10-12 Smithkline Beecham Plc Carbon side chain/indole/indolene
TW280869B (en) 1995-07-17 1996-07-11 Philips Electronics Nv IDDQ-testing of bias generator circuit
CZ287969B6 (cs) 1995-08-10 2001-03-14 Astra Pharmaceuticals Limited Amidinový derivát, způsob jeho přípravy, farmaceutický prostředek s jeho obsahem a použití
US6323227B1 (en) 1996-01-02 2001-11-27 Aventis Pharmaceuticals Products Inc. Substituted N-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides
GB9605883D0 (en) 1996-03-20 1996-05-22 Smithkline Beecham Plc Novel compounds
EP0891355A1 (en) 1996-04-03 1999-01-20 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
ES2191838T3 (es) 1996-05-11 2003-09-16 Smithkline Beecham Plc Derivados de tetrahidroisoquinoleina como moduladores de los receptores d3 de la dopamina.
NZ332757A (en) * 1996-06-17 1999-06-29 Smithkline Beecham Plc Substituted tetrahydroisoquinoline benzamide derivatives and their use as anticonvulsants and psycho-active agents
US5854245A (en) 1996-06-28 1998-12-29 Merck & Co., Inc. Fibrinogen receptor antagonists
WO1998050346A2 (en) 1997-04-18 1998-11-12 Smithkline Beecham Plc Acetamide and urea derivatives, process for their preparation and their use in the treatment of cns disorders
US6399656B1 (en) 1998-07-28 2002-06-04 Smithkline Beecham Corporation Compounds and methods
GB9817424D0 (en) 1998-08-11 1998-10-07 Smithkline Beecham Plc Novel compounds
CA2346689A1 (en) 1998-10-08 2000-04-20 Gregor James Macdonald Tetrahydrobenzazepine derivatives useful as modulators of dopamine d3 receptors (antipsychotic agents)
US7115750B1 (en) * 1999-09-20 2006-10-03 Takeda Pharmaceutical Company Limited Melanin concentrating hormone antagonist
US6531478B2 (en) 2000-02-24 2003-03-11 Cheryl P. Kordik Amino pyrazole derivatives useful for the treatment of obesity and other disorders
CN1324845A (zh) 2000-05-24 2001-12-05 上海博德基因开发有限公司 一种新的多肽——人蛋白合成起始因子2β亚单位16.5和编码这种多肽的多核苷酸
NZ523882A (en) 2000-08-21 2004-11-26 Pacific Corp Novel thiourea derivatives and the pharmaceutical compositions containing the same
WO2002017358A2 (en) 2000-08-21 2002-02-28 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists)
EP1311478B1 (en) 2000-08-21 2006-06-07 Pacific Corporation Novel (thio)urea compounds and the pharmaceutical compositions containing the same
EP1311477A4 (en) 2000-08-21 2005-01-12 Pacific Corp NEW THIOCARBAMIDIC ACID DERIVATIVES AND MEDICAMENTS CONTAINING THEM
UY26942A1 (es) 2000-09-20 2002-04-26 Abbott Lab N-acilsulfonamidas promotoras de la apoptosis

Patent Citations (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3200123A (en) * 1962-01-26 1965-08-10 Richardson Merreil Inc Imidazoquinolines
JPS4824396B1 (enExample) * 1970-09-09 1973-07-20
WO1996040640A1 (en) * 1995-06-07 1996-12-19 Pfizer Inc. BIPHENYL-2-CARBOXYLIC ACID-TETRAHYDRO-ISOQUINOLIN-6-YL AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND/OR APOLIPOPROTEIN B (Apo B) SECRETION
JP2001515504A (ja) * 1997-03-18 2001-09-18 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 置換イソキノリン誘導体およびその抗痙攣薬としての使用
JPH10291988A (ja) * 1997-04-15 1998-11-04 Fujisawa Pharmaceut Co Ltd 複素環式化合物
JP2001524116A (ja) * 1997-04-18 2001-11-27 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー ５ｈｔ１ａ、５ｈｔ１ｂおよび５ｈｔ１ｄ受容体アンタゴニスト活性を合わせ持つインドール誘導体
JP2001508402A (ja) * 1997-06-13 2001-06-26 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 置換ベンズアミド誘導体およびそれらの抗痙攣薬としての使用
JP2001521026A (ja) * 1997-10-24 2001-11-06 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 置換イソキノリン誘導体および抗痙攣薬としての使用
JPH11335355A (ja) * 1998-03-26 1999-12-07 Japan Tobacco Inc アミド誘導体及びノシセプチンアンタゴニスト
WO2000069849A1 (en) * 1999-05-12 2000-11-23 Ortho-Mcneil Pharmaceutical, Inc. Pyrazole carboxamides useful for the treatment of obesity and other disorders
WO2000073283A1 (en) * 1999-06-02 2000-12-07 Nps Pharmaceuticals, Inc. Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases
JP2001139555A (ja) * 1999-11-10 2001-05-22 Pfizer Prod Inc ７−［（４’−トリフルオロメチル−ビフェニル−２−カルボニル）アミノ］−キノリン−３−カルボン酸アミド、及びアポリポタンパク質ｂの分泌阻害方法
JP2002241274A (ja) * 2000-04-28 2002-08-28 Takeda Chem Ind Ltd メラニン凝集ホルモン拮抗剤
WO2002008221A2 (en) * 2000-07-20 2002-01-31 Neurogen Corporation Capsaicin receptor ligands
JP2004535456A (ja) * 2001-07-02 2004-11-25 アクゾ・ノベル・エヌ・ベー テトラヒドロキノリン誘導体
JP2004059567A (ja) * 2001-10-25 2004-02-26 Takeda Chem Ind Ltd キノリン化合物
JP2005518365A (ja) * 2001-11-27 2005-06-23 メルク　エンド　カムパニー　インコーポレーテッド ４−アミノキノリン化合物
JP2005519876A (ja) * 2001-11-27 2005-07-07 メルク　エンド　カムパニー　インコーポレーテッド ２−アミノキノリン化合物
JP2006505494A (ja) * 2002-02-20 2006-02-16 アボット・ラボラトリーズ バニロイド受容体サブタイプ１（ｖｒ１）受容体を阻害する縮合アザ二環式化合物

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BIOORG. MED. CHEM., vol. 8, JPN6009038033, 2000, pages 2085 - 2094, ISSN: 0001381126 *
J. MED. CHEM, vol. 38, no. 22, JPN6009038031, 1995, pages 4439 - 4445, ISSN: 0001381124 *
J. MED. CHEM., vol. 43, no. 24, JPN6009038035, 2000, pages 4667 - 4677, ISSN: 0001381127 *
REGISTRY(STN)[ONLINE], JPN7009003569, 30 October 2000 (2000-10-30), ISSN: 0001381125 *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2004103954A1 (ja) * 2003-05-20 2006-07-20 味の素株式会社 アミド誘導体
US8168827B2 (en) 2003-05-20 2012-05-01 Ajinomoto Co., Inc. Amide derivative
JP2007502258A (ja) * 2003-08-14 2007-02-08 グラクソ　グループ　リミテッド バニロイド受容体モジュレーターとして用いるためのピペリジン／シクロヘキサンカルボキサミド誘導体
JP2009541206A (ja) * 2006-03-16 2009-11-26 レノビス， インコーポレイテッド Ｐ２ｘ７調節因子としてのビシクロへテロアリール化合物およびその使用
US8546579B2 (en) 2006-03-16 2013-10-01 Evotec (Us) Inc. Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
JP2009531373A (ja) * 2006-03-27 2009-09-03 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ キナーゼ阻害剤としてのピリジル及びピリミジニル置換されたピロール、チオフェン及びフラン誘導体
JP2010512305A (ja) * 2006-10-23 2010-04-22 ファイザー株式会社 置換フェニルメチルビシクロカルボキシアミド化合物
JP2010516662A (ja) * 2007-01-19 2010-05-20 サノフイ−アベンテイス Ｎ−（ヘテロアリール）−１−ヘテロアリール−１ｈ−インドール−２−カルボキサミドの誘導体、これらの調製およびこれらの治療用途
JPWO2008091021A1 (ja) * 2007-01-24 2010-05-20 持田製薬株式会社 ヘテロシクリデン−ｎ−（アリール）アセトアミド誘導体
JP2011510052A (ja) * 2008-01-23 2011-03-31 サノフイ−アベンテイス シラニル基で置換されたインドール−２−カルボキサミドおよびアザインドール−２−カルボキサミドの誘導体、この調製、およびこの治療的使用
JP2015501826A (ja) * 2011-12-16 2015-01-19 ロレアル ７−アミノ−１，２，３，４−テトラヒドロキノリン構造を有するカプラー、それを含む染色組成物、方法及び使用
WO2016039448A1 (ja) * 2014-09-12 2016-03-17 田辺三菱製薬株式会社 芳香族カルボン酸アミド化合物

Also Published As

Publication number Publication date
WO2003068749A1 (en) 2003-08-21
US7538121B2 (en) 2009-05-26
EP1480954A1 (en) 2004-12-01
TW200403223A (en) 2004-03-01
DE60325025D1 (de) 2009-01-15
EP2033953A1 (en) 2009-03-11
AU2003245773A1 (en) 2003-09-04
US20060142333A1 (en) 2006-06-29
ATE416168T1 (de) 2008-12-15
AR038420A1 (es) 2005-01-12
ES2316777T3 (es) 2009-04-16
EP1480954B1 (en) 2008-12-03

Similar Documents

Publication Publication Date Title
US7538121B2 (en) Vanilloid receptor modulators
JP6466171B2 (ja) 新規アミン誘導体またはその塩
US7531558B2 (en) Carboxamide derivatives
US8003787B2 (en) Sulphoximine-substituted quinoline and quinazoline derivatives as kinase inhibitors
CN101851211B (zh) 一种哌嗪酰胺类化合物
EP1497291B1 (en) Quinoline and aza-indole derivatives and their use as 5-ht6 ligands
EP1414442A1 (en) 3-arylsulfonyl-7-piperazinyl- indoles, -benzofurans and -benzothiophenes with 5-ht6 receptor affinity for treating cns disorders
KR20100082390A (ko) 바닐로이드 수용체 길항제 활성이 있는 통증 치료용 우레아-화합물
JP2005508952A (ja) 尿路障害の処置における使用のためのヘテロ環式化合物
JP4988583B2 (ja) 血管内皮成長因子（ｖｅｇｆ）受容体キナーゼインヒビターとしての新規アントラニルアミドピリジンウレア
WO2005026125A1 (en) Quinoline compounds and pharmaceutical compositions containing them
EP1660483A1 (en) 8-(1-piperazinyl)-quinoline derivatives and their use in the treatment of cns disorders
CA3201443A1 (en) Tetrahydroquinoline derivative and medicinal use thereof
JP5069119B2 (ja) 血管内皮成長因子（ｖｅｇｆ）受容体キナーゼインヒビターとしてのニコチンアミドピリジンウレア
WO2004078744A2 (en) Urea derivatives and their use as vanilloid receptor antagonists in the treatment of pain
CN102558074B (zh) 含哒嗪取代基的哌嗪酰胺类化合物
KR101220328B1 (ko) 벤조사이오펜 화합물

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060117

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060117

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090728

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20090729

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20091027

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091104

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100330